vimarsana.com

Latest Breaking News On - Jain vishwa bharti institute - Page 1 : vimarsana.com

Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August

Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients. 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally. New Delhi: With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August.

Phase-3 clinical trials for 2-DG may continue till Aug: Registry data

With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August. The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients. While 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally, trials to use it as a COVID-19 drug are apparently being done in India only and incidentally, a strong case for its therapeutic use against the novel coronavirus was made in a study paper last year that had Patanjali Research Institute s Acharya Balkrishna as the lead author.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.